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Abstract
Background: Much effort goes into identifying new antimicrobial compounds able to evade the
increasing resistance of microorganisms to antibiotics. One strategy relies on antimicrobial
peptides, either derived from fragments released by proteolytic cleavage of proteins or designed
from known antimicrobial protein regions.
Results: To identify these antimicrobial determinants, we developed a theoretical approach that
predicts antimicrobial proteins from their amino acid sequence in addition to determining their
antimicrobial regions. A bactericidal propensity index has been calculated for each amino acid, using
the experimental data reported from a high-throughput screening assay as reference. Scanning
profiles were performed for protein sequences and potentially active stretches were identified by
the best selected threshold parameters. The method was corroborated against positive and
negative datasets. This successful approach means that we can spot active sequences previously
reported in the literature from experimental data for most of the antimicrobial proteins examined.
Conclusion: The method presented can correctly identify antimicrobial proteins with an accuracy
of 85% and a sensitivity of 90%. The method can also predict their key active regions, making this
a tool for the design of new antimicrobial drugs.
Background
Host defence anti-microbial proteins and peptides are
important participants of the innate immune response in
most multicellular organisms [1]. The innate immune sys-
tem comprises the cells and mechanisms that defend the
host from infection by other organisms in a non-specific
manner. Unlike the adaptive immune system, the innate
immune system does not confer a long-lasting or protec-
tive immunity to the host, but is thought to constitute an
evolutionarily older defence strategy. It remains the dom-
inant immune system in plants, fungi and insects, and
plays a crucial role during the first steps of infection in
multicellular organisms.
One of the major achievements of medicine was the
development of antibiotics, which can kill a broad spec-
trum of microorganisms. Unfortunately, the emergence of
antibiotic resistance has become a clinical threat [2,3].
Cationic proteins and peptides that are involved in innate
immunity represent an alternative strategy to conven-
tional antibiotics [4]. A considerable variety of peptides
with different size and structure are associated with anti-
microbial activity in eukaryotic hosts. Antimicrobial cati-
onic peptides have some common structural
characteristics. They are composed of 12-50 amino acids,
with 2-9 cationic residues and up to a 50% hydrophobic
amino acids [5]. Many peptides do not adopt a well-
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defined secondary structure in aqueous solution, but
adopt a specific secondary structure upon binding to
acidic phospholipids or within lipid bilayers [6].
A major limitation in the design of new antimicrobial
peptides lies in the difficulty in finding new structures
with low toxicity for the host and a broad spectrum of
action against pathogens. An important group of antimi-
crobial peptides are derived from fragments released by
proteolytic cleavage of larger proteins or derived from
known antimicrobial regions of proteins involved in the
innate immune system, such as the C-terminal domain of
cathelicidins [7] or the N-terminus of bactericidal/perme-
ability increasing protein (BPI) [8,9]. Additionally, anti-
microbial peptides often display immunomodulation
properties which can be applied in the design of new
drugs for the treatment of immune system disfunctions,
such as autoimmune diseases [10]. Knowledge of the key
regions in antimicrobial proteins is of great importance in
deriving antimicrobial peptides.
Following this approach, we present a method of predict-
ing potentially active regions of bactericidal proteins that
can serve as templates to develop agents against antimi-
crobial resistance.
Results and discussion
Method description
Experimental data based on high throughput screening
and database mining techniques show that certain resi-
dues are preferred in antimicrobial peptides. Hilpert et al.
screened all amino acid substitutions for each position of
a 12-mer peptide and tested all substitutions for activity,
which was measured as the bactericidal half-maximal
inhibitory concentration (IC50) [11].
Bactenecin (also called bovine dodecapeptide), the anti-
microbial peptide used by Hilpert et al., was discovered in
neutrophils and is active against both Gram-negative and
Gram-positive bacteria [12]. These authors used a variant
of bactenecin called Bac2A (RLARIVVIRVAR-NH2), where
internal disulfide bridges had been eliminated. Bac2A had
a high antimicrobial activity against both Gram-positive
and Gram-negative bacteria, and was used as a template to
test the effect of each amino acid substitution on the pep-
tide's activity. The IC50 value against the Pseudomonas aer-
uginosa was recorded for each synthetic peptide. Based on
the screening results, we calculated a propensity value for
each amino acid.
Although the bacterial strain for the high-throughput
assay is Gram-negative, the peptide has also been tested
against other strains [12]. The results have demonstrated
that Bac2A is a peptide with broad antimicrobial action,
which is also active against Gram-positive strains and
fungi. No differences were found between proteins with
distinct antimicrobial properties in both the training and
testing datasets. Our selected dataset covers a wide range
of antimicrobial proteins that have activity on distinct
strains from Gram-negative and Gram-positive bacteria,
and the prediction data discard any potential bias. Never-
theless, some discrepancies may arise between the pre-
dicted and experimental regions if a specific determinant
is found in a protein conferring some specificity for a par-
ticular microorganism or strain.
The calculated propensity index (Table 1), deduced from
the corresponding IC50 value for each amino acid substi-
tution, makes a good reference for the assessment of the
protein sequence determinants. Since low IC50 values cor-
respond to high antimicrobial activity, amino acids with a
lower PV value represent the most favoured to take the
part of an antimicrobial peptide. Positively charged resi-
dues (R, K) and some hydrophobic residues (W, Y, I, V)
were favoured and present a low propensity index,
whereas negatively charged residues are unfavoured and
show a high propensity index. Positively charged residues
would be necessary to direct antimicrobial proteins to the
negatively charged bacterial cell wall and cytoplasmic
membrane of bacteria, where they exert their antimicro-
bial effect [13]. Hydrophobic residues would be needed to
interact with lipophilic regions of lipid bilayers in order to
create pores or other destabilizing structures that lead to
membrane depolarization or local disruption and eventu-
ally bacterial cell death [14]. Interestingly, W has the low-
Table 1: Bactericidal propensity values (PV) for each amino 
acid.
Amino acid PV value
R0 . 1 0 6
K0 . 1 1 1
C0 . 1 6 5
W0 . 1 7 2
Y0 . 1 8 5
I0 . 1 9 8
V0 . 2 0 0
H0 . 2 0 2
N0 . 2 4 0
T0 . 2 4 2
F0 . 2 4 6
L0 . 2 4 6
Q0 . 2 4 8
G0 . 2 6 5
M0 . 2 6 5
S0 . 2 8 1
A0 . 3 0 7
P0 . 3 2 7
E0 . 4 4 9
D0 . 4 7 9
Calculations are based on the average half maximal inhibitory 
concentration, as detailed in the Methods section.BMC Bioinformatics 2009, 10:373 http://www.biomedcentral.com/1471-2105/10/373
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est PV value among the hydrophobic residues, whereas L
has the highest value, while I and V rather than L, are pre-
ferred. In fact, W residues are known to be important for
antimicrobial peptide action [15].
Because bactericidal action is generally located in a spe-
cific region, a sliding window system of 7 residues was
chosen for the screening approach. To improve the predic-
tive accuracy, 3 predictive lengths of 10, 12 and 14 resi-
dues were evaluated. For each length, the optimal number
of permissible gaps was tested (2, 3 or 4 gaps). For each
combination of parameters, an ROC curve was con-
structed, and the accuracy, sensitivity and selectivity of the
method calculated in order to select the best parameters
[see Additional file 1: Supplemental Figures S1, S2 and
S3]. Optimal results were obtained using a predictive
length of 12 amino acids allowing 2 gaps (Table 2). For
these conditions, the AvPV threshold value was 0.225;
thus residues with an AvPV <0.225 were considered
favourable whereas residues with an AvPV >0.225 were
considered unfavourable. Allowing a higher gap number
drastically lowered both the specificity and sensitivity, so
only 2 gaps were allowed. Using the selected cut-off value
(a predictive length of 12 residues with 2 allowed gaps)
we achieved an accuracy value of 85%, a sensitivity of
90%, and a specificity of 80% (Table 2).
Although this method detects antimicrobial regions with
high accuracy, it may not be adequate in predicting anti-
microbial regions with a high content of some specific
amino acids, e.g. proline. Likewise, F residues are consid-
ered to favor antimicrobial activity [16], but this residue
has a relatively high calculated index. Our method has
been constructed with data provided from a peptide with
particular amino acid content, and this may slightly alter
the effect of some of the substitutions and the final output
of their assigned propensity values. This may increase the
number of target proteins missed, but do not alter the sig-
nificance of the positive hits. In any case, the propensity
indexes can be recalculated as other experimental data
become available, to update and improve the method pre-
diction power.
Method testing and implementation
The proposed method was applied to a set of 100 proteins
(50 bactericidal proteins and 50 non-bactericidal). Repre-
sentative members of the main antimicrobial protein fam-
ilies described in the literature were included, and the
results were compared and discussed with the available
experimental data (Table 3).
Most of the known antimicrobial proteins were correctly
identified and their active region was accurately predicted,
when adequate information was available (Table 3).
To probe its reliability, the method was also applied to a
positive testing dataset containing 20 antimicrobial pro-
teins. It predicted 90% of the proteins in it. A negative test-
ing dataset was also analyzed and 81% of the proteins
were correctly identified as non-antimicrobial proteins.
The results obtained are in good agreement with those
presented for the training dataset [see Additional file 1:
Supplemental Tables S1 and S2].
We describe below the main representative families of
antimicrobial proteins that were examined, together with
an exhaustive comparison between the predicted identi-
fied sequences and the experimentally active reported
regions (Table 3).
Cathelicidins comprise a family of mammalian proteins
expressed in epithelial and myeloid cells, involved in the
innate immune response [10]. Cathelicidins contain a C-
terminal cationic antimicrobial domain that becomes
active on release from the N-terminal region of the holo-
protein [17]. The most studied form is the human catheli-
cidin antimicrobial protein of 18 kDa (hCAP18). Its C-
terminus (LL-37) has a wide spectrum of antimicrobial
activity and other biological activities [18]. Analysis of the
human cathelicidin sequence leads to the prediction that
the LL-37 peptide region is responsible for antimicrobial
activity (hCAP 18, Table 3).
This family comprises other known antimicrobial pep-
tides active against a great variety of bacteria, including
CAP11 or CRAMP, with a very low sequence identity and
distinct assigned active regions. In all cases, antimicrobial
regions predicted span the sequence corresponding to
experimentally reported active peptides (CAP11 and
CRAMP, Table 3) [19,20].
Bactericidal/permeability-increasing protein (BPI) is a 456-
residue cationic protein stored in the polymorphonuclear
leukocytes primary granules [21]. During phagocytosis
and degranulation, proteases cleave BPI in the 236-241
Table 2: Evaluation of the tested parameter values for the 
selection of optimal predicting length and gap inclusion.
Predictive length (Gaps) Sensitivity Specificity
10 (2) 92% 78%
10 (3) 86% 82%
10 (4) 92% 78%
12 (2) 90% 80%
12 (3) 88% 82%
12 (4) 86% 84%
14(2) 86% 84%
14 (3) 86% 84%
14 (4) 84% 86%BMC Bioinformatics 2009, 10:373 http://www.biomedcentral.com/1471-2105/10/373
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region, releasing the fragment corresponding to the N-ter-
minus end [8]. This fragment is responsible for its antibac-
terial activity [22]. Our method predicts 2 potential
antimicrobial regions in the N-terminus of, in good agree-
ment with the reported experimental data (BPI, Table 3).
One of these regions (rBPI21) is reported to be clinical
useful [23]. The other region is a potent endotoxin neu-
tralizing peptide, thus providing a potential therapeutic
value for peptides tested (USA Patent 5830860).
Histone H2A is one of the 5 main histone proteins
involved in the structure of chromatin. Buforin I is a 39
amino acids peptide encoded by the same gene as histone
H2A. A specific protease responsible for the generation of
buforin I from histone H2A is in the crude extracts of the
toad stomach, suggesting the presence of a specific func-
tional regulation mechanism which converts toad histone
H2A to buforin I. Moreover, a more potent antimicrobial
peptide of 21 amino acids, buforin II, derived from
buforin I [24,25] shows high antimicrobial activity
against a broad spectrum of microorganisms. The histone
H2A sequence screening analysis shows 2 potential anti-
microbial regions. The first predicted sequence is part of
buforin II sequence (Histone H2A, Table 3). There seems
to be no report of any experimental evidence for the sec-
ond region predicted. However, the ratio between charged
and hydrophobic residues makes this peptide a good tar-
get to test.
Lysozyme is an antibacterial protein with activity against
Gram-positive and Gram-negative bacteria; muramidase
activity is considered responsible for its bactericidal activ-
ity [26]. However, the denatured protein is also active,
showing that lysozyme retains its antimicrobial activity
when muraminidase activity is absent. In addition, some
derived peptides from the lysozyme C-terminus, e.g. pep-
tide A4 (residues 143-155), also retain antimicrobial
activity [27,28]. These results agree with our prediction
about this region in bacteriophage T4 lysozyme (Lysozyme,
Table 3), further supporting the hypothesis that bacteri-
Table 3: Detail of the predicted sequences from the studied antimicrobial proteins.
Proteins Identified sequences Experimental data reported
hCAP 18 RKSKEKIGKEFKRIVQRIKD LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES [17]
CAP 11 LGGRRFRRMVGLRKKFRKTRKRIQKLGRKIGKTGRKV
WKAW
GLRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQ
IPYPCRI [19]
CRAMP RFKKKISLRAGLLRKGG.... EKLKKIGQKIKNFFQ
SVRFRVKETV
ISLRAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE 
[21]
BPI SVHVHISKSKVGWLIQLFHK
NCIKISGKWKAQKRFLK
KSKVGWLIQLFHKK [23]
ISNANIKISGKWKAQKRFLKMSGNFDLSI*
Histone H2A GRGKQGGKVRAKAKTRS//GRVHRLLRKG
KKTRIIPRHLQL
SGRGKQGGKVRAKAKSRSSRAGLQFPVGRVHRLLRK
GNY [25]
Lysozyme AKSRWYNQTPNRAKRVITTFRT WDEAAVNLAKSRWYN[27]
Azurocidin SGGRLSRFPRFVNV
PNNVCTGVLTRRGGI
50% sequence identity with protegrin antimicrobial peptides
α-defensin YGTCIYQGRLWAFCC RYGTCIYQGRLWAFS[36]
β-defensin TLQKYYCRVRGGRCAVLSC
KCSTRGRKCCRRKK
GIINTLQKYYSRVRGGR
KSSTRGRKSSRRKK[37]
θ-defensin GLRCICTRGFCRLL RCICTRGFCRLL[39]
Magainin precursor IGKFLHSAKKFGK GIGKFLHSAKKFGKAFVGEIMNS [40]
Moronecidin HIFRGIVHVGKTIHRLVT FFHHIFRGIVHVGKTIHKLVTG [44]
Pleurocidin FFKKAAHVGKHVG GWGSFFKKAAHVGKHVGKAALTHYL [45]
Bacteriocin enterocin SCNKKGSCPGVKYGKKLGG KYYGNGVSCNKKGCSV[49]
Helveticin J VVQKGNVGSKYVYGLQLRKGA No active peptide reported
Sarcotoxin IA WLKKIGKKIERVGQ W35 is described as a key residue in endotoxin neutralizing 
activity [52]
RNase 3 INNYRWRCKNQNTFLR
VNVCGNQSIRCPHNRTLNNCHRSRFRVPL
TIAMRAINNYRWRSKNQNTFLR[61]
RNase 7 NINKHTKRCK
SHGRVSLTMCKLTSGKYPNCRYKEKRQNKSYVVA
No active peptide reported
SPAG 11K QLLRHPVKRAPIIRRIP N -terminus suggested [68]
Hepcidin LCRFCCKCCRNKGCGYCCKF No active peptide reported
Ace AMP1 ICPRVNRIVT
VNTRNLRRAACRCLVGVVNRNPGLRRNPR
RNTFVRPFWWRPRIQCGRI
No active peptide reported
* United States Patent n° 5830860
The first column includes the identified sequences by the prediction approach. The corresponding active peptides previously described in the 
literature and tested experimentally are included in the adjacent column for comparison. Matching residues between the identified and 
experimentally active sequences are underlined and highlighted in bold.BMC Bioinformatics 2009, 10:373 http://www.biomedcentral.com/1471-2105/10/373
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cidal activity of lysozyme is not uniquely attributed to its
muramidase activity.
Serprocidins are 25-37 kDa serine proteases localized in
neutrophil granules with cytotoxic activity against both
Gram-negative and Gram-positive bacteria [29].
There is no evidence for a defined antimicrobial region in
azurocidin, the human serprocidin. Although a peptide
comprising the region 20-44 has been suggested [30], sub-
sequent studies found no direct correlation between this
segment and antimicrobial activity [31].
Our results also suggest that 2 other regions are involved
in the bactericidal activity of azurocidin. Of special inter-
est is the predicted antimicrobial region SGGRLSRF-
PRFVNV that shows a 53% of identity with protegrins
(Azurocidin, Table 3), a group of antimicrobial peptides in
porcine leukocytes that exhibit in vitro broad-spectrum
antimicrobial activity [32,33].
Defensins  are a family of antimicrobial peptides [34]
showing antimicrobial activity against Gram-negative and
Gram-positive bacterial strains, fungi, and some parasites
and enveloped viruses. Defensins can be classified by ori-
gin and structure. Vertebrate α and β defensins share a
common fold and are mainly distinguished according to
their disulfide bridge pattern, while θ defensins are α-
derived cyclic peptides.
Our results predict a main antimicrobial region for α-
defensins in agreement with published data (α-defensin,
Table 3). The prediction screening points to the C-termi-
nus of α-defensins as the key region that retain antimicro-
bial activity. Recent studies on the antimicrobial activity
of α-defensins also support this hypothesis [35].
In analysing human β-defensin, we identified a potential
active sequence at both the N- and C-termini. The C-ter-
minal sequence of β-defensins retains the antimicrobial
capacity of the whole protein against Gram-negative bac-
teria. Moreover, the N-terminal sequence seems to be nec-
essary for activity against Gram-positive bacteria and
fungi. Thus, the contribution of both N- and C-termini is
not completely understood, but seems necessary to have
broad spectrum antimicrobial activity [36,37]. These find-
ings coincide with the prediction results, suggesting that
the whole protein is involved in its antimicrobial action
(β-defensin, Table 3).
Finally, we have predicted the active domain described in
Rhesus macaque θ-defensin (θ-defensin, Table 3) [38,39].
Magainins are a class of antimicrobial peptides discovered
in the skin of Xenopus laevis [40-42]. In analyzing the
magainin precursor that contains 5 copies of the active
peptide, and our method can identify the active segments
(Magainin precursor, Table 3).
Piscidins were the first antimicrobial cationic peptides to
be isolated from the mast cells of striped bass fish [43]. We
have analyzed the potential antimicrobial regions of 2
proteins: moronecidin and pleurocidin (Moronecidin,
pleurocidin, Table 3). The predictions are in good agree-
ment with the experimentally tested peptides, which, in
both cases, correspond to the mature peptide released
after the cleavage of the propeptide region from the pro-
tein [44,45].
Bacteriocins, antimicrobial proteins or peptides produced
by bacteria, are expressed in lactic acid bacteria (LAB)
[46,47].
We have analyzed bacteriocins, which have been the most
studied peptides. For bacteriocin enterocin CRL35, the
region predicted at its N-terminus overlaps with some
sequences tested in literature (Bacteriocin enterocin, Table
3) [48]. We have also analyzed bacteriocin helveticin-J,
and identified a potential antimicrobial region, but there
is no data on the region responsible for its activity to cor-
roborate this prediction (Helveticin-J, Table 3).
Sarcotoxin IA is a cecropin-like polycationic peptide that is
active against a wide range of both Gram-positive and
Gram-negative bacteria [49]. The natural 62 amino acid
precursor of sarcotoxin is processed, resulting in a 39
amino acid long mature peptide [50]. No region has been
described for sarcotoxin IA as primarily responsible for its
antimicrobial action. However, key residues have been
identified as important in the bactericidal activity of sar-
cotoxin IA, specifically W35, implicated in endotoxin-
neutralizing activity [51]. W35 residue lies in the pre-
dicted potential antimicrobial region (Sarcotoxin IA, Table
3). Moreover, our predicted sequence shows 45% amino
acid identity with salmocidins, an antimicrobial peptide
group isolated from Salmo gairdneri, which has still to be
characterized (deposited in SwissProt P81369).
Antimicrobial ribonucleases The RNase A family includes
RNases with cytotoxic and antipathogen properties [52-
54].
The eosinophil cationic protein (ribonuclease 3 or ECP) is
a human host defence ribonuclease involved in inflam-
matory processes mediated by eosinophils [55,56]. ECP is
a potent cytotoxic molecule, with bactericidal and
helminthotoxic properties [57]. ECP antimicrobial activ-
ity is dependent on its action at the cytoplasmic mem-
brane and bacteria wall [58,60]. Our recent experimental
data confirm that the first predicted sequence (RNase 3,BMC Bioinformatics 2009, 10:373 http://www.biomedcentral.com/1471-2105/10/373
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Table 3) is involved in the protein bactericidal activity
[61]. Screening of the membrane lysis and bactericidal
activity of RNase 3 derived peptides corroborated that the
protein N-terminus region retains most of its antimicro-
bial activity. The role of the second predicted region
remains to be determined.
Ribonuclease 7 is an antimicrobial protein expressed in
skin, liver, kidney, skeletal muscle and heart. RNase 7 has
a high antimicrobial activity against P. aeruginosa and P.
Pastoris, and a lower effect in S. aureus and E. coli cells [62-
64]. RNase 7 site-directed mutagenesis studies indicate
that some lysine clusters are necessary for the protein anti-
microbial action, although not every cluster is of equal
importance [64]. In this context, the regions predicted by
our theoretical approach include a great number of lysine
residues, giving them a high cationic content (RNase 7,
Table 3). Nevertheless, the selected sequences present a
low hydrophobic residue content in contrast to most
known antimicrobial regions. As the RNase 7 antibacterial
mechanism has not been identified, we cannot yet explain
these results.
Conclusion
Recently, much attention has been paid to develop com-
putational methods to screen and synthesize antimicro-
bial peptides. High throughput screening tests provide a
powerful tool to design predictive methods. A method
using high throughput screening that predicts antimicro-
bial action of peptides in P. aeruginosa has been published
[65]. Other screening and bioinformatics approaches in
the quest for new antimicrobial agents have recently been
described. Lata et al. [66] designed a program to predict
antimicrobial peptides, based in the observation that cer-
tain types of residues are preferred over others, particu-
larly at the N- and C- termini. Using a support vector
machine, this approach is a powerful tool with which to
predict or identify antimicrobial peptides.
Our method differs from previously reported predictive
algorithms because it applies experimentally derived high
throughput screening values obtained in synthetic pep-
tides to analyse protein sequences. Few attempts have
been made to analyse bactericidal proteins to identify the
structural determinants for their mechanism of action.
The proposed predictive screening approach has been
applied to the main characterized antimicrobial protein
families, allowing a direct comparison between the iden-
tified sequences and previous experimental data. We cor-
roborate that the predicted sequences mostly match the
regions experimentally reported by others. Moreover, our
own experimental data testing a RNase 3 peptide collec-
tion was also proven successful [61]. Other antimicrobial
proteins (SPAG 11K, Hepcidin and Ace AMP1) have also
been analysed and successfully predicted as antimicrobial
proteins (Table 3). In these cases, no other experimental
results have been reported, which precludes direct confir-
mation of the capacity of the prediction method. How-
ever, the results presented here provide an opportunity to
study predicted peptides. To further optimize the method
prediction power we are planning to update the provided
indexes as new high throughput screening results become
available.
Thus, this method can give a first approach in spotting the
key regions of bactericidal proteins that give them their
activity. The selected regions may provide a useful starting
point in the development of new antimicrobial peptide
derived drugs.
Methods
Sequence analysis
Protein sequences were obtained from the Swiss-Prot/
TrEMBL Database http://www.ebi.ac.uk/swissprot/. Pair-
wise and multiple alignments were made with ClustalW
http://www.ebi.ac.uk/Tools/clustalw2. Multiple align-
ments with known antimicrobial peptides were per-
formed using the Antimicrobial Peptide Database http://
aps.unmc.edu/AP/main.php/[67].
Data processing and model design
To predict potential antimicrobial regions, a bactericidal
propensity index value (PV) was calculated for each
amino acid. To ascribe a PV value to each, we took the
experimental data of Hilpert et al. [11] where a complete
library of 12 amino acid peptides was generated, starting
from a template based on a linearized variant of
bactenecin, a bovine antimicrobial peptide (Bac2A). From
a high-throughput screening assay, activity against Pseu-
domonas aeruginosa for each amino acid substitution was
tested and the bactericidal inhibitory concentration (IC50)
value for each peptide was estimated [11]. Using these
experimental data, the average minimal inhibitory con-
centration (called the propensity value, PV) was calcu-
lated for each residue (Table 1). Each propensity value
corresponds to the arithmetical average between the 12
positions tested in the peptide Bac2A. The standard error
associated with each score has an constant value of
approximately 0.05.
The screening for antimicrobial regions is based on the
calculated bactericidal propensity values per amino acid
(PV), using the IC50 experimental values, as already dis-
cussed. The method calculates the average propensity
value (AvPV) over a sliding window of the length of 7 res-
idues and assigns this value to the central residue inside
the window. The window size was selected to ensure the
best signal/noise ratio for the tested sequences. The use of
smaller window size may overestimate some regions,BMC Bioinformatics 2009, 10:373 http://www.biomedcentral.com/1471-2105/10/373
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whereas using larger window sizes may lose some infor-
mation.
A protein is classified as antimicrobial if it has at least one
antimicrobial region. To define a region in a sliding win-
dow system, 2 parameters were considered: the minimal
length of the region (called the predictive length) and the
allowed gap inclusion. In this case, 3 different predicting
lengths of 10, 12 and 14 residues were tested, making
allowance for 2, 3 or 4 gaps in each case.
Protein datasets
A training dataset of 50 antimicrobial proteins, compris-
ing some of the best characterized antimicrobial protein
families in the literature, was selected for evaluation.
Some of the proteins sequence determinants have been
reported experimentally, allowing a further checking of
predicted results and experimental data. To complete the
training dataset, 50 non-antimicrobial proteins recorded
in the Swiss-Prot database were included. These proteins
were randomly selected among those reported as soluble
and having between 50 and 200 amino acid residues.
To assess the predictability of the method, a positive test-
ing dataset has also been constructed, containing 20 anti-
microbial proteins verified and annotated as
antimicrobial according to Swiss-Prot. Another dataset,
containing 20 soluble proteins has been constructed to
provide a negative testing dataset. No proteins belonging
to the training dataset were included in both cases [see
Additional file 1: Supplemental Tables S1 and S2].
Evaluation of the method
To assess the performance of the method and determine
the best cut-off AvPV value for each case, we used the
Receiver Operating Characteristic (ROC) curves, consider-
ing the parameters described below:
True positive (TP) and true negative (TN) are correctly pre-
dicted as antimicrobial proteins and non-antimicrobial
proteins, respectively. False positive (FP) and false nega-
tive (FN) are wrongly predicted antimicrobial proteins
and predicted non-antimicrobial proteins, respectively.
MCC is the Matthew's correlation coefficient.
For each case, we constructed an ROC curve and deter-
mined its parameters as described in Table 2. Once the
best ROC curve had been gained, the cut-off AvPV value
was evaluated and the protein sequences were assayed
using these values.
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